Takeda sells $660M in assets to Stada Arzneimittel

Takeda dipped into its pool of non-core assets again and sold $660 million to Stada Arzneimittel as part of its goal to divest $10 billion in non-core assets.

Advertisement

What you should know:

1. Takeda sold assets related to over-the-counter vitamins and food supplements, as well as cardiovascular, diabetes, general medicine and respiratory therapeutic products.

2. Takeda has completed six similar transactions recently as it attempts to pay off debt.

3. After acquiring Shire in January 2019, Takeda became one of the largest and most indebted drugmakers in the world.

More articles on surgery centers: 
3 ways to improve ASC revenue cycle performance
Indiana legislators meet resistance on price transparency bill
Maximizing reimbursements in ASCs: A review of reimbursement methodology

At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.

Register to Attend Webinar

Unlocking Structural Heart Capacity: How Leading Programs Use EMR and Data to Improve Patient Flow and Throughput

Wednesday, August 19
11:00 AM - 12:00 PM CDT

Presenters: Katie Kennedy, MSN, APRN, NP-C, Community Heart and VascularMisty Theriot, BSN, RN, CPHQ, FACC, Lake Charles Memorial Health SystemKatie Worthington, DNP, RN, Atlantic Health SystemTaryn Shipley, MBA, CSSBB, Lean HealthTech

Advertisement

Next Up in GI & Endoscopy

Advertisement

Comments are closed.